Rational arguments for regulatory acceptance of consistency testing: benefits of non-animal testing over in vivo release testing of vaccines

References

• International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Q8(R2) on pharmaceutical development. 2009. https://www.ich.org/page/quality-guidelines. (Accessed 25 Feb 2023)
   Google Scholar
• De Mattia F, Chapsal JM, Descamps J, et al. The consistency approach for quality control of vaccines - a strategy to improve quality control and implement 3rs. Biologicals. 2011;39:59–65.
   PubMedGoogle Scholar
• De Mattia F, Hendriksen C, Buchheit KH, et al. The vaccines consistency approach project: an EPAA initiative. Pharmeur Bio Sci Notes. 2015;2015:30–56.
   PubMedGoogle Scholar
• Romberg J, Lang S, Balks E, et al. Potency testing of veterinary vaccines: the way from in vivo to in vitro. Biologicals. 2012;40:100–106.
   PubMed Web of Science ®Google Scholar
• den Biggelaar Rhga V, Hoefnagel MHN, Vandebriel RJ, et al. Overcoming scientific barriers in the transition from in vivo to non-animal batch testing of human and veterinary vaccines. Expert Rev Vaccines. 2021;20(10):1221–1233. DOI:10.1080/14760584.2021.1977628
   PubMed Web of Science ®Google Scholar
• Stalpers CAL, Retmana IA, Pennings JLA, et al. Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines. Vaccine. 2021;39(18):2506–2516. DOI:10.1016/j.vaccine.2021.03.078.
   PubMed Web of Science ®Google Scholar
• Stalpers CAL, Retmana IA, Pennings JLA, et al. Corrigendum to “Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines” [Vaccine, 39(18)(2021), 2506-2516]. Vaccine. 2022;40(23):3272–3273. DOI:10.1016/j.vaccine.2022.04.047
   PubMed Web of Science ®Google Scholar
• EDQM. General chapter 5.2.14 Substitution of in vivo methods by in vitro methods for the quality control of vaccines. In: European Pharmacopoeia 11th. Strasbourg France: European Department for the Quality of Medicines; 2023. p. 716–718.
   Google Scholar
• European Medicines Agency (2016). EMA/CHMP/CVMP/JEG-3Rs/450091/2012. Guideline on the principles of regulatory acceptance of 3rs (replacement, reduction, refinement) testing approaches. https://www.ema.europa.eu/en/regulatory-acceptance-3r-replacement-reduction-refinement-testing-approaches#current-effective-version-section
   Google Scholar
• Weißer K, Hechler U. Animal welfare aspects in the quality control of immunologicals – a critical evaluation of the animal tests in pharmacopoeial monographs. Nottingham: FRAME, Russel & Birch House; 1997.
   Google Scholar
• Riches-Duit R R, Hassall L, Kogelman A, et al. Characterisation of diphtheria monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay. Biologicals. 2021;69:38–48.
   PubMed Web of Science ®Google Scholar
• Metz B, Jiskoot W, Hennink WE, et al. Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines. Vaccine. 2003;22(2):156–167. DOI:10.1016/j.vaccine.2003.08.003
   PubMed Web of Science ®Google Scholar
• Coombes L, Stickings P, Tierney R, et al. Development and use of a novel in vitro assay for testing of diphtheria toxoid in combination vaccines. J Immunol Methods. 2009;350(1–2):142–149. DOI:10.1016/j.jim.2009.09.002
   PubMed Web of Science ®Google Scholar
• Coombes L, Tierney R, Rigsby P, et al. In vitro antigen ELISA for quality control of tetanus vaccines. Biologicals. 2012;40:466–472.
   PubMed Web of Science ®Google Scholar
• World Health Organization WHO Technical Report Series, No. 897 (2000) Annex 1 recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines 1. https://www.who.int/publications/m/item/hib-conjugate-vaccines-annex-1-trs-no-897. (Accessed 25 Feb 2023)
   Google Scholar
• Descamps J, Giffroy D, Remy E, et al. A case study of development, validation, and acceptance of a non-animal method for assessing human vaccine potency. Procedia in Vaccinology. 2011;5:184–191.
   Google Scholar
• McFarland R, Verthelyi D, Casey W, et al. Non-animal replacement methods for human vaccine potency testing: state of the science and future directions. Procedia in Vaccinology. 2011;5:16–32.
   PubMedGoogle Scholar
• Isbrucker R, Daas A, Wagner L. Costanzo a Transferability study of CHO cell clustering assays for monitoring of pertussis toxin activity in acellular pertussis vaccines. Pharmeur Bio Sci Notes. 2016;2015:97–114.
   PubMedGoogle Scholar
• EDQM. Text 2.6.33. Residual pertussis toxin. In: European pharmacopoeia. 11th ed. Strasbourg France: European Department for the Quality of Medicines; 2023. p. 254–256.
   Google Scholar
• EDQM. Text 2.7.6. Assay of diphtheria vaccine (adsorbed). In: European pharmacopoeia. 11th ed. Strasbourg France: European Department for the Quality of Medicines; 2023. p. 285–290.
   Google Scholar
• Sesardic D, Prior C, Daas A, et al. Collaborative study for establishment of the European Pharmacopoeia BRP batch 1 for diphtheria toxin. Pharmeuropa Bio. 2003;2003:5–21. PMID: 14563306.
   PubMedGoogle Scholar
• Maas RA, Komen M, van Diepen M, et al. Correlation of haemagglutinin-neuraminidase and fusion protein content with protective antibody response after immunisation with inactivated Newcastle disease vaccines. Vaccine. 2003;21(23):3137–3142. DOI:10.1016/S0264-410X(03)00249-4
   PubMed Web of Science ®Google Scholar
• Claassen I, Maas R, Oei H, et al. Validation study to evaluate the reproducibility of a candidate in vitro potency assay of Newcastle disease vaccines and to establish the suitability of a candidate biological reference preparation. Pharmeuropa Bio. 2004;2004:1–15.
   PubMedGoogle Scholar
• Krämer B, Kamphuis E, Hanschmann KM, et al. A multi-dose serological assay suitable to quantify the potency of inactivated rabies vaccines for veterinary use. Biologicals. 2013;41:400–406.
   PubMed Web of Science ®Google Scholar
• Chabaud-Riou M, Moreno N, Guinchard F, et al. G-protein based ELISA as a potency test for rabies vaccines. Biologicals. 2017;46:124–129.
   PubMed Web of Science ®Google Scholar
• Toinon A, Moreno N, Chausse H, et al. Potency test to discriminate between differentially over-inactivated rabies vaccines: agreement between the NIH assay and a G-protein based ELISA. Biologicals. 2019;60:49–54.
   PubMed Web of Science ®Google Scholar
• EDQM. Text 0451. Rabies vaccine (inactivated) for veterinary use. In: European Pharmacopoeia. 11th ed. Strasbourg France: European Department for the Quality of Medicines; 2023. p. 1210–1212.
   Google Scholar
• Sawyer LA, McInnis J, Albrecht P. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains. Biologicals. 1993;21:169–177.
   PubMed Web of Science ®Google Scholar
• EDQM. Text 2.7.20. In vivo assay of poliomyelitis vaccine (inactivated). In: European pharmacopoeia. 11th ed. Strasbourg France: European Department for the Quality of Medicines; 2023. p. 304–305.
   Google Scholar
• Dunn G, Chumakov KM Standard operating procedure: mutant analysis by PCR and restriction enzyme cleavage (MAPREC) for oral poliovirus (Sabin) vaccine types 1, 2 or 3. World Health Organization, 2011. https://www.who.int/biologicals/vaccines/MAPREC_SOP_Final_09112012.pdf. (Accessed 25 Feb 2023)
   Google Scholar
• Charlton B, Hockley J, Laassri M, et al. The use of next-generation sequencing for the quality control of live-attenuated polio vaccines. J Infect Dis. 2020;222(11):1920–1927. DOI:10.1093/infdis/jiaa299
   PubMed Web of Science ®Google Scholar
• Charlebois RL, Sathiamoorthy S, Logvinoff C, et al. Sensitivity and breadth of detection of high-throughput sequencing for adventitious virus detection. NPJ Vaccines. 2020;5:61.
   PubMed Web of Science ®Google Scholar
• EDQM. Text 2.6.16. Tests for extraneous agents in viral vaccines for human use. In: European Pharmacopoeia. 11th ed. Strasbourg France: European Department for the Quality of Medicines; 2023. p. 230–232.
   Google Scholar
• Khan AS, Blümel J, Deforce D, et al. Report of the second international conference on next generation sequencing for adventitious virus detection in biologics for humans and animals. Biologicals. 2020;67:94–111.
   PubMed Web of Science ®Google Scholar
• Cleveland MH, Anekella B, Brewer M, et al. Report of the 2019 NIST-FDA workshop on standards for next generation sequencing detection of viral adventitious agents in biologics and biomanufacturing. Biologicals. 2020;64:76–82.
   PubMed Web of Science ®Google Scholar
• A BNH, Bonifas U, Hanschmann KM, et al. Binding and cleavage (BINACLE) assay for the functional in vitro detection of tetanus toxin: applicability as alternative method for the safety testing of tetanus toxoids during vaccine production. Vaccine. 2013;31(52):6247–6253. DOI:10.1016/j.vaccine.2013.10.028.
   PubMed Web of Science ®Google Scholar
• Stokes W, McFarland R, Kulpa-Eddy J, et al. Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward. Biologicals. 2012;40:369–381.
   PubMed Web of Science ®Google Scholar
• Poston R, Hill R, Allen C, et al. Achieving scientific and regulatory success in implementing non-animal approaches to human and veterinary rabies vaccine testing: a NICEATM and IABS workshop report. Biologicals. 2019;60:8–14.
   PubMed Web of Science ®Google Scholar
• Soni D, Sahoo I, Mallya AD, et al. Development of competitive inhibition ELISA as an effective potency test to analyze human rabies vaccines and assessment of the antigenic epitope of rabies glycoprotein. J Immunol Methods. 2021;492:112939.
   PubMed Web of Science ®Google Scholar
• Riches-Duit R, Hassall L, Rigsby P, et al. Evaluation of a capture antigen ELISA for the characterisation of tetanus vaccines for veterinary use. Biologicals. 2019;61:8–14.
   PubMed Web of Science ®Google Scholar
• Riches-Duit R, Hassall L, Kogelman A, et al. Characterisation of tetanus monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay. Biologicals. 2021;71:31–41.
   PubMed Web of Science ®Google Scholar
• Ticha O, Klemm D, Moos L, et al. A cell-based in vitro assay for testing of immunological integrity of Tetanus toxoid vaccine antigen. NPJ Vaccines. 2021;6(1):88.
   PubMed Web of Science ®Google Scholar
• Michiels TJM, Tilstra W, Hamzink MRJ, et al. Degradomics-based analysis of tetanus toxoids as a quality control assay. Vaccines. 2020;8(4):712. DOI:10.3390/vaccines8040712
   Web of Science ®Google Scholar
• Michiels TJM, van Veen MA, Meiring HD, et al. Common reference-based tandem mass tag multiplexing for the relative quantification of peptides: design and application to degradome analysis of diphtheria toxoid. J Am Soc Mass Spectrom. 2021;32(2):1490–1497. DOI:10.1021/jasms.1c00070
   PubMedGoogle Scholar
• Signorazzi A, Etna MP, Coccia EM, et al. In vitro assessment of tick-borne encephalitis vaccine: suitable human cell platforms and potential biomarkers. ALTEX. 2021;38:431–434.
   PubMedGoogle Scholar
• van den Biggelaar RHGA, van der Maas L, Meiring HD, et al. Proteomic analysis of chicken bone marrow-derived dendritic cells in response to an inactivated IBV + NDV poultry vaccine. Sci Rep. 2021;11(1):12666. DOI:10.1038/s41598-021-89810-3
   PubMed Web of Science ®Google Scholar
• van den Biggelaar RHGA, van Eden W, Rutten VPMG, et al. Macrophage activation assays to evaluate the immunostimulatory capacity of avibacterium paragallinarum in a multivalent poultry vaccine. Vaccines (Basel). 2020;8(4):671.
   PubMed Web of Science ®Google Scholar
• EDQM. Text 5.2.3. Cell substrates for the production of vaccines for human use. In: European Pharmacopoeia. 11th ed. Strasbourg France: European Department for the Quality of Medicines; 2023. p. 682–686.
   Google Scholar
• WHO Expert Committee on Biological Standardization. (2018) 69th report: wHO TRS N°1016. https://www.who.int/publications/i/item/9789241210256. (Accessed 25 Feb 2023)
   Google Scholar
• Schutte K, Szczepanska A, Halder M, et al. Modern science for better quality control of medicinal products “Towards global harmonization of 3rs in biologicals”: the report of an EPAA workshop. Biologicals. 2017;48:55–65.
   PubMed Web of Science ®Google Scholar
• EDQM. Text 1356. Pertussis vaccine (acellular, component, adsorbed). In: European pharmacopoeia. 11th ed. Strasbourg France: European Department for the Quality of Medicines; 2023. p. 1079–1081.
   Google Scholar
• EDQM. Text 1595. Pertussis vaccine (acellular, co-purified, adsorbed). In: European pharmacopoeia. 11th ed. Strasbourg France: European Department for the Quality of Medicines; 2023. p. 1081–1082.
   Google Scholar
• EMA (2012) Bexsero EPAR EMA/790069/2012 https://www.ema.europa.eu/en/documents/assessment-report/bexsero-epar-public-assessment-report_en.pdf. (Accessed 25 Feb 2023)
   Google Scholar
• EMA (2017) Trumenba EPAR EMA/CHMP/232746/2017 https://www.ema.europa.eu/documents/assessment-report/trumenba-epar-public-assessment-report_en.pdf. (Accessed 25 Feb 2023)
   Google Scholar
• Tesolin L Biological reference standards for multivalent vaccines qualification strategies and challenges from a national control lab perspective. Presented at CASSS BIOASSAYS 2020: scientific approaches & regulatory strategy session on technical aspects of bioassays throughout the product. 2020 Apr 27; Gaithersburg PA. https://www.sciensano.be/en/biblio/biological-reference-standards-multivalent-vaccines-qualification-strategies-and-challenges-a. (Accessed 25 Feb 2023)
   Google Scholar
• Boraschi D, Li D, Li Y, et al. In Vitro and in vivo models to assess the immune-related effects of nanomaterials. Int J Environ Res Public Health. 2021;18(22):11769.
   PubMed Web of Science ®Google Scholar
• Rehberger K, Escher BI, Scheidegger A, et al. Evaluation of an in vitro assay to screen for the immunotoxic potential of chemicals to fish. Sci Rep. 2021;11(1):3167. DOI:10.1038/s41598-021-82711-5
   PubMed Web of Science ®Google Scholar
• Xing D, Yuen CT, Asokanathan C, et al. Evaluation of an in vitro assay system as a potential alternative to current histamine sensitization test for acellular pertussis vaccines. Biologicals. 2012;40:456–465.
   PubMed Web of Science ®Google Scholar
• Barone PW, Keumurian FJ, Neufeld C, et al. Historical evaluation of the in vivo adventitious virus test and its potential for replacement with next generation sequencing (NGS). Biologicals. 2023:101661. DOI:10.1016/j.biologicals.2022.11.003
   PubMed Web of Science ®Google Scholar
• Gombold J, Karakasidis S, Niksa P, et al. Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products. Vaccine. 2014;32(24):2916–2926. DOI:10.1016/j.vaccine.2014.02.021
   PubMed Web of Science ®Google Scholar
• Ntp.Niehs.nih.gov/Go/40399. Accepted alternative methods for biologics and vaccine testing. https://ntp.niehs.nih.gov/whatwestudy/niceatm/test-method-evaluations/biologics-and-vaccines/vaccine-testing/index.html. (Accessed 10 Dec 2022)
   Google Scholar
• Center for Veterinary Biologics. Supplemental assay method for in vitro potency testing of Leptospira interrogans serogroup pomona bacterins (2017). Testing Protocol SAM 624, United States Department of Agriculture, Center for Veterinary Biologics. https://www.aphis.usda.gov/animal_health/vet_biologics/publications/624.pdf. (Accessed 25 Feb 2023).
   Google Scholar
• McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–1117. DOI:10.1126/science.1234914
   PubMed Web of Science ®Google Scholar
• Barrett AD, Teuwen DE. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol. 2009;21(3):308–313.
   PubMed Web of Science ®Google Scholar
• Ghattas M, Dwivedi G, Lavertu M, et al. Vaccine technologies and platforms for infectious diseases: current progress, challenges, and opportunities. Vaccines (Basel). 2021;9(12):1490.
   PubMed Web of Science ®Google Scholar
• Ura T, Takeuchi M, Kawagoe T, et al. Current vaccine platforms in enhancing T-Cell response. Vaccines (Basel). 2022;10(8):1367.
   PubMed Web of Science ®Google Scholar
• http://www.vac2vac.eu/. VAC2VAC Vaccine batch to vaccine batch comparison by consistency testing. (Accessed 22 Dec 2022).
   Google Scholar
• Zhu D, Huang S, McClellan H, et al. Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer. Vaccine. 2012;30(2):189–194. DOI:10.1016/j.vaccine.2011.11.025
   PubMed Web of Science ®Google Scholar
• Rinella JV, Workman RF, Hermodson MA, et al. Elutability of proteins from aluminum-containing vaccine adjuvants by treatment with surfactants. J Colloid Interface Sci. 1998;197(1):48–56. DOI:10.1006/jcis.1997.5230
   PubMed Web of Science ®Google Scholar
• Vandebriel RJ, Stalpers CAL, Vermeulen JP, et al. Development of a cell line-based in vitro assay for assessment of diphtheria, tetanus and acellular pertussis (DTaP)-induced inflammasome activation. Vaccine. 2022;40(38):5601–5607. DOI:10.1016/j.vaccine.2022.08.022
   PubMed Web of Science ®Google Scholar
• Akkermans A, Chapsal JM, Coccia EM, et al. Animal testing for vaccines. Implementing replacement, reduction and refinement: challenges and priorities. Biologicals. 2020;68:92–107.
   PubMed Web of Science ®Google Scholar